company background image
PRO

Societe de Promotion Pharmaceutique du MaghrebCBSE:PRO Stock Report

Market Cap

د.م1.2b

7D

0%

1Y

61.6%

Updated

18 Oct, 2021

Data

Company Financials
PRO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends0/6

PRO Overview

Societe de Promotion Pharmaceutique du Maghreb S.A.

Price History & Performance

Summary of all time highs, changes and price drops for Societe de Promotion Pharmaceutique du Maghreb
Historical stock prices
Current Share Priceد.م1,170.00
52 Week Highد.م690.00
52 Week Lowد.م1,180.00
Beta0.21
1 Month Change0%
3 Month Change26.08%
1 Year Change61.60%
3 Year Change15.84%
5 Year Change6.46%
Change since IPO19.75%

Recent News & Updates

Shareholder Returns

PROMA PharmaceuticalsMA Market
7D0%2.4%1.0%
1Y61.6%87.5%26.4%

Return vs Industry: PRO underperformed the MA Pharmaceuticals industry which returned 87.5% over the past year.

Return vs Market: PRO exceeded the MA Market which returned 26.4% over the past year.

Price Volatility

Is PRO's price volatile compared to industry and market?
PRO volatility
PRO Beta0.21
Industry Beta0.56
Market Beta1

Stable Share Price: Insufficient data to determine PRO's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine PRO's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1947n/aMa'mon Salameh Alaraidehhttps://www.promopharm.co.ma

Societe de Promotion Pharmaceutique du Maghreb S.A. produces, commercializes, imports, and exports medicines, derma-pharmaceuticals, and cosmetic products in Africa. It also subcontracts medicines for national and international laboratories. The company was founded in 1947 and is headquartered in Had-Soualem, Morocco.

Societe de Promotion Pharmaceutique du Maghreb Fundamentals Summary

How do Societe de Promotion Pharmaceutique du Maghreb's earnings and revenue compare to its market cap?
PRO fundamental statistics
Market Capد.م1.17b
Earnings (TTM)د.م60.26m
Revenue (TTM)د.م573.20m

19.4x

P/E Ratio

2.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PRO income statement (TTM)
Revenueد.م573.20m
Cost of Revenueد.م272.81m
Gross Profitد.م300.38m
Expensesد.م240.12m
Earningsد.م60.26m

Last Reported Earnings

Dec 31, 2020

Next Earnings Date

n/a

Earnings per share (EPS)60.26
Gross Margin52.41%
Net Profit Margin10.51%
Debt/Equity Ratio0%

How did PRO perform over the long term?

See historical performance and comparison

Valuation

Is Societe de Promotion Pharmaceutique du Maghreb undervalued compared to its fair value and its price relative to the market?

19.42x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PRO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PRO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PRO is poor value based on its PE Ratio (19.4x) compared to the African Pharmaceuticals industry average (9.4x).

PE vs Market: PRO is good value based on its PE Ratio (19.4x) compared to the MA market (26.8x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PRO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PRO is overvalued based on its PB Ratio (3x) compared to the XF Pharmaceuticals industry average (1.6x).


Future Growth

How is Societe de Promotion Pharmaceutique du Maghreb forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Societe de Promotion Pharmaceutique du Maghreb has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Societe de Promotion Pharmaceutique du Maghreb performed over the past 5 years?

-14.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PRO has high quality earnings.

Growing Profit Margin: PRO's current net profit margins (10.5%) are higher than last year (10%).


Past Earnings Growth Analysis

Earnings Trend: PRO's earnings have declined by 14.5% per year over the past 5 years.

Accelerating Growth: PRO's earnings growth over the past year (15.7%) exceeds its 5-year average (-14.5% per year).

Earnings vs Industry: PRO earnings growth over the past year (15.7%) exceeded the Pharmaceuticals industry 10%.


Return on Equity

High ROE: PRO's Return on Equity (15.7%) is considered low.


Financial Health

How is Societe de Promotion Pharmaceutique du Maghreb's financial position?


Financial Position Analysis

Short Term Liabilities: PRO's short term assets (MAD451.8M) exceed its short term liabilities (MAD151.0M).

Long Term Liabilities: PRO's short term assets (MAD451.8M) exceed its long term liabilities (MAD9.5M).


Debt to Equity History and Analysis

Debt Level: PRO's debt to equity ratio (0%) is considered satisfactory.

Reducing Debt: PRO's debt to equity ratio has reduced from 0.09% to 0% over the past 5 years.

Debt Coverage: Insufficient data to determine if PRO's debt is well covered by operating cash flow.

Interest Coverage: PRO earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Societe de Promotion Pharmaceutique du Maghreb current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PRO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PRO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: PRO is not paying a notable dividend for the MA market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PRO's dividend in 3 years as they are not forecast to pay a notable one for the MA market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Ma'mon Salameh Alaraideh

no data

Tenure

Mr. Ma'mon Salameh Muhaisen Alaraideh serves as Chief Executive Officer at Societe de Promotion Pharmaceutique du Maghreb S.A. and serves as its Director.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Societe de Promotion Pharmaceutique du Maghreb S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Societe de Promotion Pharmaceutique du Maghreb S.A.
  • Ticker: PRO
  • Exchange: CBSE
  • Founded: 1947
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: د.م1.170b
  • Shares outstanding: 1.00m
  • Website: https://www.promopharm.co.ma

Number of Employees


Location

  • Societe de Promotion Pharmaceutique du Maghreb S.A.
  • Rue 7, zone industrielle du Sahel
  • BP 96/97
  • Had-Soualem
  • 26 400
  • Morocco

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 16:30
End of Day Share Price2021/10/08 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.